Cash and Investments: $50.7 billion
Annual Operating Cash Flow: $17.1 billion
Revenue Per Employee: $629,000
Once again, we return to the recession-proof healthcare sector with big pharma heavyweight Pfizer (PFE).
You may fret about patent expirations and generic competition, but the massive war chest at this pharmaceutical company allows it to both research new cures and snap up smaller biotech firms that are developing cures Pfizer will eagerly absorb into its lineup.
The cash cushion is immense and the 3.3% dividend yield is an added incentive for long-term investors who are looking to hunker down in a low-risk play.